PHARMA
PHARMAPharmaceutical Hydrogenation Membrane in United States
Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. The US hydrogen market is accelerating under the Inflation Reduction Act's production tax credits (up to $3/kg for clean hydrogen) and the DOE's $7 billion Regional Clean Hydrogen Hubs program.
Market Context
United StatesPolicy
H₂ Target
Cities
Industries
Ultra-Clean Hydrogen Source
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
GMP-Compatible On-Site Generation
On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.
Batch-Flexible Operation
Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.
Pharmaceutical Hydrogenation in United States’s Hydrogen Market
The US hydrogen market is accelerating under the Inflation Reduction Act's production tax credits (up to $3/kg for clean hydrogen) and the DOE's $7 billion Regional Clean Hydrogen Hubs program. Houston, Pittsburgh, and California are focal points for hydrogen production, with applications spanning refineries, steel, ammonia, and transport. American electrolyser manufacturers are scaling rapidly to capture IRA incentives.
IONZERA helps US hydrogen projects maximize IRA credits by reducing the electricity cost per kg of hydrogen through 3x lower membrane resistance. For American electrolyser OEMs, IONZERA provides a high-performance membrane source that diversifies supply beyond European single-supplier dependency.
Lower Resistance
Thinner Profile
PERFORMANCE ADVANTAGE
Why IONZERA for Pharmaceutical Hydrogenation in United States
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
Shipping & Logistics
Air freight from India to US hubs (Houston, LA, NYC) in 5-8 business days. Sea freight 4-6 weeks.
Area Resistance
3x LOWERThickness
20% THINNERPharmaceutical Hydrogenation Membrane in United States Cities
Frequently Asked Questions
Why choose IONZERA for pharmaceutical hydrogenation in United States?
IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in United States. IONZERA helps US hydrogen projects maximize IRA credits by reducing the electricity cost per kg of hydrogen through 3x lower membrane resistance.
How does IONZERA improve the economics of IRA-supported hydrogen projects?
The IRA provides up to $3/kg production tax credit for clean hydrogen. IONZERA's 3x lower membrane resistance reduces electricity consumption per kg of H2, lowering production costs and maximizing the net benefit of IRA incentives for alkaline electrolysis projects.
Can IONZERA be used in DOE Regional Clean Hydrogen Hub projects?
Yes. IONZERA is a drop-in replacement for conventional AWE membranes, compatible with standard alkaline electrolyser stacks. Hub projects using alkaline electrolysis can benefit from IONZERA's superior efficiency and competitive pricing.
EXPLORE MORE
Request Pharmaceutical Hydrogenation Samples for United States
Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for United States-based projects.
Request Sample